---
title: 'Genetic Characterization of Primary Mediastinal B-Cell Lymphoma: Pathogenesis
  and Patient Outcomes'
date: '2023-12-06'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38055913/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20231207170746&v=2.17.9.post6+86293ac
source: heidelberg[Affiliation]
description: 'CONCLUSION: This large-scale genomic characterization of PMBCL identified
  novel treatment targets and genetic lesions for refined risk stratification. DUSP2
  and CD58 mutation analyses may guide treatment decisions between rituximab plus
  cyclophosphamide, doxorubicin, vincristine, and prednisone and dose-adjusted etoposide,
  prednisone, vincristine, cyclophosphamide, doxorubicin, and ...'
disable_comments: true
---
CONCLUSION: This large-scale genomic characterization of PMBCL identified novel treatment targets and genetic lesions for refined risk stratification. DUSP2 and CD58 mutation analyses may guide treatment decisions between rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone and dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and ...